Federated Hermes Inc. Has $76.26 Million Position in Guardant Health, Inc. $GH

Federated Hermes Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 72.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,465,438 shares of the company’s stock after purchasing an additional 615,429 shares during the quarter. Federated Hermes Inc. owned 1.18% of Guardant Health worth $76,261,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Signaturefd LLC grew its stake in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after buying an additional 213 shares during the last quarter. American Century Companies Inc. grew its position in Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after acquiring an additional 282 shares during the last quarter. IFP Advisors Inc grew its position in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the last quarter. Main Management ETF Advisors LLC increased its holdings in Guardant Health by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after purchasing an additional 348 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after purchasing an additional 469 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

GH opened at $102.02 on Monday. Guardant Health, Inc. has a fifty-two week low of $29.91 and a fifty-two week high of $112.43. The firm has a market capitalization of $12.86 billion, a PE ratio of -31.78 and a beta of 1.58. The company’s 50-day moving average is $84.67 and its 200 day moving average is $63.43.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. The company’s revenue was up 38.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.88) EPS. As a group, analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling

In other Guardant Health news, insider Terilyn J. Monroe sold 55,167 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the sale, the insider directly owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. This represents a 72.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,500 shares of Guardant Health stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $95.19, for a total transaction of $142,785.00. Following the transaction, the director directly owned 815 shares in the company, valued at approximately $77,579.85. This represents a 64.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 368,228 shares of company stock worth $24,835,525. 6.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GH. Mizuho set a $100.00 price target on Guardant Health in a research note on Thursday, October 30th. TD Cowen boosted their target price on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Leerink Partners upped their price target on shares of Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Wells Fargo & Company began coverage on shares of Guardant Health in a report on Monday, September 22nd. They set an “overweight” rating and a $72.00 price target on the stock. Finally, Barclays increased their price objective on Guardant Health from $70.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $80.86.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.